Organovo Holdings, Inc. (NASDAQ:ONVO) spotted trading -64.58% off 52-week high price. On the other end, the stock has been noted 37.80% away from the low price over the last 52-weeks. The stock changed 5.15% to recent value of $0.51. The stock transacted 665070 shares during most recent day however it has an average volume of 2464.79K shares. The company has 108.99M of outstanding shares and 108.99M shares were floated in the market.
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious diseases, presented data on fabricating stem cell-based kidney tissues at The International Society for Stem Cell Research 2019 Annual Meeting held in Los Angeles, Ca. from June 26-29, 2019.
Organovo has continued to adapt stem-cell based approaches to developing kidney tissues using its leading 3D bioprinting platform. The Company has demonstrated the automated production of complex kidney organoids, with potential future applications including in vitro disease modeling and the treatment of patients with renal disease.
“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues,” said Taylor J. Crouch, CEO, Organovo. “Our recently announced collaboration with Murdoch Children’s Research Institute (“MCRI”) and Professor Melissa Little has made our work automating the fabrication of kidney organoids possible. By combining MCRI’s proprietary approach for modeling human kidney tissue from stem cells and Organovo’s 3D bioprinting platform, we’re able to produce detailed kidney tissues, which is a key step toward advancing this promising technology for both drug testing and therapeutic applications. We’re hopeful that this will be an important step along the way in treating kidney disease.”
Its earnings per share (EPS) expected to touch remained 28.90% for this year . ONVO has a gross margin of 84.40% .
According to the most recent quarter its current ratio was 10.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 7.02% from the mean of 20 days, -25.00% from mean of 50 days SMA and performed -46.71% from mean of 200 days price. Company’s performance for the week was 3.09%, 11.92% for month and YTD performance remained -46.71%.